1.35
price down icon8.16%   -0.12
after-market アフターアワーズ: 1.37 0.02 +1.48%
loading
前日終値:
$1.47
開ける:
$1.43
24時間の取引高:
1.60M
Relative Volume:
0.75
時価総額:
$92.47M
収益:
$5.03M
当期純損益:
$-185.41M
株価収益率:
-0.4369
EPS:
-3.09
ネットキャッシュフロー:
$-139.79M
1週間 パフォーマンス:
-15.09%
1か月 パフォーマンス:
-60.76%
6か月 パフォーマンス:
-87.96%
1年 パフォーマンス:
-90.94%
1日の値動き範囲:
Value
$1.33
$1.43
1週間の範囲:
Value
$1.33
$1.644
52週間の値動き範囲:
Value
$1.26
$16.52

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
名前
Pliant Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
650-481-6770
Name
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
PLRX's Discussions on Twitter

PLRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.35 92.47M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-04 再開されました Cantor Fitzgerald Neutral
2025-03-04 ダウングレード Needham Buy → Hold
2025-03-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-03-03 ダウングレード Stifel Buy → Hold
2025-02-10 ダウングレード Canaccord Genuity Buy → Hold
2025-02-10 ダウングレード Citigroup Buy → Neutral
2025-02-10 ダウングレード H.C. Wainwright Buy → Neutral
2025-02-10 ダウングレード JP Morgan Overweight → Neutral
2025-02-10 ダウングレード Oppenheimer Outperform → Perform
2025-02-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-10 ダウングレード Wells Fargo Overweight → Equal Weight
2024-09-09 再開されました Leerink Partners Outperform
2023-12-08 開始されました Wells Fargo Overweight
2023-05-18 開始されました Canaccord Genuity Buy
2023-04-13 開始されました Robert W. Baird Outperform
2022-12-14 開始されました Stifel Buy
2022-12-07 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Buy
2022-07-20 開始されました SVB Leerink Outperform
2022-05-25 開始されました Cantor Fitzgerald Overweight
2021-12-10 開始されました Oppenheimer Outperform
2021-11-24 開始されました RBC Capital Mkts Outperform
2021-11-03 開始されました H.C. Wainwright Buy
2021-04-20 開始されました BTIG Research Buy
2021-04-05 開始されました Citigroup Buy
2020-06-29 開始されました Citigroup Buy
2020-06-29 開始されました Cowen Outperform
2020-06-29 開始されました Needham Buy
2020-06-29 開始されました Piper Sandler Overweight
すべてを表示

Pliant Therapeutics Inc (PLRX) 最新ニュース

pulisher
Mar 28, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PR Newswire

Mar 28, 2025
pulisher
Mar 27, 2025

PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - TradingView

Mar 27, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics – PLRX - MENAFN.COM

Mar 26, 2025
pulisher
Mar 23, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 23, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire Inc.

Mar 23, 2025
pulisher
Mar 21, 2025

TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Pliant Therapeutics Inc - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Pliant discontinues Phase 2b/3 trial of IPF treatment bexotegrast - Pulmonary Fibrosis News

Mar 21, 2025
pulisher
Mar 21, 2025

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com

Mar 21, 2025
pulisher
Mar 19, 2025

Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright - Defense World

Mar 19, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics Announces Interim Phase 1 Data for - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Markets Insider

Mar 17, 2025
pulisher
Mar 17, 2025

Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial - Marketscreener.com

Mar 17, 2025
pulisher
Mar 14, 2025

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Yahoo Finance

Mar 14, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics adopts shareholder rights plan By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals

Mar 13, 2025
pulisher
Mar 13, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve

Mar 13, 2025
pulisher
Mar 13, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus.com

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics adopts shareholder rights plan - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan

Mar 13, 2025
pulisher
Mar 09, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM

Mar 09, 2025
pulisher
Mar 06, 2025

Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Leerink Partners Downgrades Pliant Therapeutics (MUN:9PT) - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

If You Don’t Bullish On Pliant Therapeutics Inc (NASDAQ: PLRX) Now, You’ll Regret Your Decision Later - Stocks Register

Mar 05, 2025
pulisher
Mar 05, 2025

Pliant halts lung fibrosis trial amid safety concerns - The Pharma Letter

Mar 05, 2025
pulisher
Mar 05, 2025

Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $3.00 by Analysts at Royal Bank of Canada - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX - PR Newswire

Mar 04, 2025
pulisher
Mar 04, 2025

Leerink Partners Downgrades Pliant Therapeutics (PLRX) - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Pliant Therapeutics stock tumbles amid IPF trial cancellation - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future - Benzinga

Mar 04, 2025
pulisher
Mar 04, 2025

Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Pliant downgraded at Stifel on bexotegrast trial discontinuation - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Pliant stock downgraded at Stifel trial discontinuation (PLRX:NASDAQ) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 04, 2025

This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Mar 04, 2025
pulisher
Mar 04, 2025

Stifel Downgrades Pliant Therapeutics to Hold From Buy, Adjusts Price Target to $3 From $32 - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Needham Downgrades Pliant Therapeutics to Hold From Buy -March 04, 2025 at 08:28 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Pliant Therapeutics: Hold Rating Maintained Amid Trial Discontinuation and Adjusted Financial Outlook - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Pliant Therapeutics Reports Q4 2024 Results and Updates - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Pliant Therapeutics price target lowered to $1.50 from $4 at Citi - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral By Investing.com - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Cautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial Outlook - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization - TipRanks

Mar 04, 2025

Pliant Therapeutics Inc (PLRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):